SCINOPHARM TAIWAN LTD

Founded in 1997, Taiwan Shenlong is an international active pharmaceutical ingredient (API) company that provides comprehensive development and manufacturing services for APIs and intermediates. It not only supplies major generic pharmaceutical companies worldwide but also offers API outsourcing services to new drug development companies and patented major pharmaceutical companies. The company's main factory is located in the Tainan Science Park, covering an area of 6.6 hectares. It is an API factory complying with US FDA and international GMP standards, a multi-functional batch-type chemical synthesis plant capable of producing a variety of products. Equipped with an advanced process monitoring system, it carries out highly automated CGMP production operations. As a major international supplier of APIs, Taiwan Shenlong focuses on anti-cancer drugs as its core generic API products and is one of the leading international suppliers of anti-cancer generic APIs. In addition to anti-cancer related products, it also develops APIs for central nervous system and gastrointestinal diseases, with a wide range of product types. In terms of contract research and development of new drugs, Shenlong provides international major pharmaceutical companies and biotech new drug companies with API process development and production services for clinically needed drugs. In product development, Taiwan Shenlong focuses on the development of high-tech APIs, with technical capabilities including small-molecule organic synthesis and peptide compounds, and a complete R&D capacity. Since the company's product processes are independently developed and do not infringe on other existing patents, coupled with its profound R&D and technical capabilities, it has established a strong competitive edge in the fiercely competitive international market. Its global customers include international patented pharmaceutical companies and the world's top ten generic pharmaceutical companies, making it one of the important sources of pharmaceutical raw materials in the global biopharmaceutical industry. Taiwan Shenlong has also expanded into the downstream injectable preparation field, providing customers with one-stop services from APIs to injectable preparations. The company will focus on the development of high-end special APIs and preparations, adopting the "Double A" model, namely the dual engines of API (Active Pharmaceutical Ingredient) and ANDA (Abbreviated New Drug Application), to seize the global market. Taiwan's anti-cancer injection factory is the starting point of this strategy, which is believed to further consolidate and expand Shenlong's existing API business, enhance the company's long-term competitive advantage and expand growth space.